Iovance Biotherapeutics (NASDAQ:IOVA) reported quarterly losses of $(0.53) per share which missed the analyst consensus estimate of $(0.51) by 3.92 percent. This is a 12.77 percent decrease over losses of $(0.47) per share from the same period last year.
Related Posts
Stifel Bumps Up Caesars Entertainment Price Target By 6%
Stifel analyst Steven Wieczynski raised the price target on Caesars Entertainment Inc (NASDAQ:CZR) to $127 from $120 and kept a Buy rating on…
Bristol Myers Squibb Scores Three Back To Back European Approvals For Opdivo In Esophageal, Urothelial Cancer
The European Commission (EC) has approved Bristol Myers Squibb Co's (NYSE: BMY) Opdivo (nivolumab) plus Yervoy (ipilimumab)
Barclays Maintains Equal-Weight on Dell Technologies, Lowers Price Target to $41
Barclays analyst Tim Long maintains Dell Technologies (NYSE:DELL) with a Equal-Weight and lowers the price target from $49 to $41.